Coverage
-
February 23, 2016
With its ruling Monday that Warner Chilcott's noncash settlements with generics makers over its contraceptive Loestrin could face antitrust scrutiny, the First Circuit fell into line with other courts and brought some possible closure to the debate over whether a "payment" under the U.S. Supreme Court's Actavis decision must be cash, attorneys say.
9 other articles on this case.
View all »